NSAIDs gastropathies in clinician’s practice
- Autores: Bakulin I.G.1, Avalueva E.B.1, Bakulina N.V.1, Serkova M.Y.1, Berest D.G.1, Pavlova E.Y.1
-
Afiliações:
- I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia
- Edição: Volume 10, Nº 3 (2024)
- Páginas: 153-163
- Seção: ACTUAL ISSUES OF PHARMACOTHERAPY AND PREVENTIVE TREATMENT
- URL: https://journals.eco-vector.com/2412-4036/article/view/633898
- DOI: https://doi.org/10.18565/therapy.2024.3.153-163
- ID: 633898
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Current review presents current information about risk factors, epidemiology of NSAIDs gastropathy in Russia and throughout the world, and provides a comparative description of nonsteroidal anti-inflammatory drugs (NSAID) in terms of the incidence of this complication and their influence at the digestive tract. Peculiarities of outpatients with NSAIDS gastropathy are covered, and the algorithm for managing such patients is discussed in details using a clinical case as an example.
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
Igor Bakulin
I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia
Autor responsável pela correspondência
Email: igbakulin@yandex.ru
ORCID ID: 0000-0002-6151-2021
MD, Dr. Sci. (Medicine), professor, head of the Department of propaedeutics of internal diseases, gastroenterology and dietetics named after S.M. Ryss
Rússia, Saint PetersburgElena Avalueva
I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia
Email: avalueva@mail.ru
ORCID ID: 0000-0001-6011-0998
MD, Dr. Sci. (Medicine), professor of the Department of propaedeutics of internal diseases, gastroenterology and dietetics named after S.M. Ryss
Rússia, Saint PetersburgNatalya Bakulina
I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia
Email: nv_bakulina@mail.ru
ORCID ID: 0000-0003-4075-4096
MD, Dr. Sci. (Medicine), professor, head of the Department of internal medicine, nephrology, general and clinical pharmacology with a pharmacy course
Rússia, Saint PetersburgMargarita Serkova
I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia
Email: serkova.margarita@yandex.ru
ORCID ID: 0000-0001-9600-3131
MD, PhD (Medicine), assistant at the Department of propaedeutics of internal diseases, gastroenterology and dietetics named after S.M. Ryss
Rússia, Saint PetersburgDmitry Berest
I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia
Email: berestdg@mail.ru
MD, PhD (Medicine), associate professor of the Department of faculty surgery with a course of endoscopy named after I.I. Grekov, head of the Department of endoscopy of the Hospital named after Peter the Great
Rússia, Saint PetersburgElena Pavlova
I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia
Email: epavlova.doc@mail.ru
MD, PhD (Medicine), assistant at the Department of propaedeutics of internal diseases, gastroenterology and dietetics named after S.M. Ryss
Rússia, Saint PetersburgBibliografia
- Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(S1): 1–29. [Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018; 56(S1): 1–29 (In Russ.)]. https://doi.org/10.14412/rjtao20180. EDN: PCPKRP.
- Аналитический отчет DSM Group. Итоги 2022 года: аптечный сегмент лекарственных препаратов. Доступ: https://dsm.ru/docs/analytics/Annual_report_2023_rus.pdf (дата обращения – 04.04.2024). [Analytical report of DSM Group. Results of 2022: Pharmaceutical segment of medicines. URL: https://dsm.ru/docs/analytics/Annual_report_2023_rus.pdf (date of access – 04.04.2024) (In Russ.)].
- Циммерман Я.С. Поражение желудка, индуцированное приемом нестероидных противовоспалительных препаратов (НПВП): НПВП-гастрит или НПВП-гастропатия? Клиническая фармакология и терапия. 2018; 27(1): 14–21. [Tsimmerman Ya.S. Gastric damage induced by nonsteroidal anti-inflammatory drugs (NSAIDs): NSAID gastritis or NSAID gastropathy? Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2018; 27(1): 14–21 (In Russ.)]. EDN: YVJSHS.
- Маев И.В., Андреев Д.Н., Дичева Д.Т. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обусловленные подходы к профилактике и терапии. Фарматека. 2016; (2): 49–54. [Maev I.V., Andreev D.N., Dicheva D.T. NSAID-induced gastropathies: Pathogenetically substantiated approaches to prevention and therapy. Farmateka. 2016; (2): 49–54 (In Russ.)]. EDN: VMICOR.
- Lanza F.L., Chan F.K.., Quigley E.M. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009; 104: 728–38. https://doi.org/10.1038/ajg.2009.115. PMID: 19240698.
- Silverstein F.E., Graham D.Y, Senior J.R. et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123(4): 241–49. https://doi.org/10.7326/0003-4819-123-4-199508150-00001. PMID: 7611589.
- Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов. Клиническая медицина. 2000; 78(3): 4–10. [Nasonov E.L., Karateev A.E. Gastric lesions associated with non-steroidal anti-inflammatory drugs. Klinicheskaya meditsina = Clinical Medicine. 2000; 78(3): 4–10 (In Russ.)]. EDN: GPBVBT.
- Dequerker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large Scale Evaluation of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998; 37(9): 946–51. https://doi.org/10.1093/rheumatology/37.9.946. PMID: 9783758.
- Stam W., Jansen J., Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: A mixed treatment comparison. Open Rheumatol J. 2012; 6: 6–20. https://doi.org/10.2174/1874312901206010006. PMID: 22582102. PMCID: PMC3349945.
- Yang M., Wang H.T., Zhao M. et al. Network meta-analysis comparing relatively selective COX-2 inhibitors versus coxibs for the prevention of NSAID-induced gastrointestinal injury. Medicine (Baltimore). 2015; 94(40): e1592. https://doi.org/10.1097/MD.0000000000001592. PMID: 26448006. PMCID: PMC4616749.
- Каратеев А.Е. Российский опыт применения нимесулида: обзор клинических испытаний. Consilium Medicum. 2011; 13(9): 89–95. [Karateev A.E. Russian experience with nimesulide: Review of clinical trials. Consilium Medicum. 2011; 13(9): 89–95 (In Russ.)]. EDN: RASPJZ.
- Каратеев А.Е., Цурган А.В. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017; 11(4): 89–94. [Karateev A.E., Tsurgan A.V. Aceclofenac: The experience of Russian studies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017; 11(4): 89–94 (In Russ.)]. https://doi.org/10.14412/1996-7012-2017-4-89-94. EDN: ZXYAHP.
- Chan F.K., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet. 2010; 376(9736): 173–79. https://doi.org/10.1016/S0140-6736(10)60673. PMID: 20638563.
- Conforti A., Leone R., Moretti U. et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: Results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001; 24(14): 1081–90. https://doi.org/10.2165/00002018-200124140-00006. PMID: 11735663.
- Feng X., Tian M., Zhang W., Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018; 13(1): e0190798. https://doi.org/10.1371/journal.pone.0190798. PMID: 29320568. PMCID: PMC5761870.
- Захарова Н.В., Бакулин И.Г., Симаненков В.И., Маслыгина А.А. Обзор рекомендаций пятого Маастрихтского/Флорентийского консенсуса по диагностике и лечению инфекции Helicobacter pylori. Фарматека. 2016; (S5): 8–26. [Zakharova N.V., Bakulin I.G., Simanenkov V.I., Maslygina A.A. Review of the Maastricht V / Florence consensus recommendations on the diagnosis and treatment of Helicobacter pylori infection. Farmateka. 2016; (S5): 8–26 (In Russ.)]. EDN: XSDFXR.
- Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2007; 369(9560): 465–73. https://doi.org/10.1016/S0140-6736(07)60234-7. PMID: 17292766.
- Laine L., Curtis S.P., Langman M. et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008; 135(5): 1517–25. https://doi.org/10.1053/j.gastro.2008.07.067. PMID: 18823986.
- Garg A., Shoeb A., Moodahadu L.S. et al. Amtolmetin: A reappraisal of NSAID with gastroprotection. Arthritis. 2016; 2016: 7103705. https://doi.org/10.1155/2016/7103705. PMID: 27092274. PMCID: PMC4820613.
- Трухан Д.И. Нестероидные противовоспалительные препараты сквозь призму коморбидности и лекарственной безопасности: в фокусе – амтолметин гуацил. Consilium Medicum. 2015; 17(2): 27–33. [Trukhan D.I. Nonsteroidal anti-inflammatory drugs through the prism comorbidity and drug safety: In focus amtolmetin guatsil. Consilium Medicum. 2015; 17(2): 27–33 (In Russ.)]. EDN: TVLTCH.
- Castellsague J., Riera-Guardia N., Calingaert B. et al. Individual NSAIDs and upper gastrointestinal complications: A systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35(12): 1127–46. https://doi.org/10.2165/11633470-000000000-00000.
- Морозова Т.Е., Рыкова С.М., Чукина М.А. НПВП-гастропатии у больных с сочетанной патологией сердечно-сосудистой системы и заболеваниями суставов и позвоночника. Экспериментальная и клиническая гастроэнтерология. 2015; (6): 64–70. [Morozova T.E., Rykova S.M., Chukina M.A. NSAID gastropathy in patients with comorbid diseases. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2015; (6): 64–70 (In Russ.)]. EDN: UHYNMD.
- Шостак Н.А., Рябкова А.А., Савельев В.С., Малярова Л.П. Желудочно-кишечные кровотечения, как осложнение гастропатий, связанных с приемом НПВП. Терапевтический архив. 2003; 75(5): 70–73. [Shostak N.A., Ryabkova A.A., Savelyev V.S., Malyarova L.P. Gastrointestinal hemorrhages as complications of gastropathies associated with intake of non-steroid anti-inflammatory drugs. Terapevticheskiy arkhiv = Therapeutic Archive. 2003; 75(5): 70–73 (In Russ.)]. EDN: OJZQIH.
- Захарова Н.В., Симаненков В.И., Бакулин И.Г. с соавт. Распространенность хеликобактерной инфекции у пациентов гастроэнтерологического профиля в Санкт-Петербурге. Фарматека. 2016; (S5): 33–39. [Zakharova N.V., Simanenkov V.I., Bakulin I.G. et al. Prevalence of Helicobacter pylori infection in gastroenterological patients in Saint Petersburg. Farmateka. 2016; (S5): 33–39 (In Russ.)]. EDN: XSDGAJ.
Arquivos suplementares
![](/img/style/loading.gif)